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Abstract
AKT/mTOR and Wnt/β-catenin cascades are frequently deregulated in human tumors.
And we established a mouse model by co-expression of AKT and β-catenin mutants
(S33Y, S45Y) in mouse liver using the sleeping beauty transposon/transposase system
via hydrodynamic tail vein injection. The mice showed large liver tumors at 14-15 weeks
post injection for the AKT/S45Y-β-catenin group, and 16 weeks for the AKT/S33Y-βcatenin group. All tumors displayed notable lipid accumulation in hepatocytes.
The molecular signal pathway changed in the model including p-ERK, p-AKT, and
mTORC1/mTORC2 related gene Raptor, Rictor, p-4ebp1, PS6.IHC staining and
western blot showed beta-catenin and its downstream target gene GS, CCND1 were
upregulated in the model. Meanwhile, myc was increased in the tumor groups
compared to the normal mice. To demonstrate their relative contribution in the HCC
model, we sub-cloned shRNA against various downstream targets and co-delivered with
AKT and β-catenin mutants by hydrodynamic tail vein injection, including shRaptor,
shRictor, shMYC, shYap, shTAZ. Suppression of key target genes of yap, myc and
raptor notably affected tumorigenesis in AKT/beta-catenin s45y group, but only shYap
and shRaptor could inhibit tumor development in AKT/beta-catenin s33y group. Such
results showed there exist difference tumorigenesis function of beta-catenin s33y and
beta-catenin s45y when they cross-talk with other oncogene. Another study showed that
when we blocked downstream target binding protein of beta-catenin in vivo, namely codeliver AKT/beta-catenin mutation and dnTCF4 to the mice liver, there were no tumors
around 21 weeks post hydrodynamic tail vein injection, the results showed TCF4 is
required for the tumor development in the model.

Thus, while differences in β-catenin mutations can lead to differing extents of β-catenin
activation, -catenin does cooperate with AKT to induce HCC with lipogenic phenotype.
Yap and mTORC1 pathway is indispensable for AKT/beta-catenin mutant induced HCC,
and these dysregulated target gene might be used for precise therapy with the model.
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